Preview

Вопросы современной педиатрии

Расширенный поиск

БОЛЕЗНЬ КАВАСАКИ — НОВЫЕ ДАННЫЕ

Аннотация

В лекции представлены современные данные о болезни Кавасаки — острого васкулита неясной этиологии, возникающего преимущественно у детей в возрасте до 5 лет. Описаны существующие алгоритмы диагностики и стратификации риска при болезни Кавасаки, освещены современные рекомендации по лечению детей с этим заболеванием и особенностям их ведения после выздоровления.

Ключевые слова: дети, болезнь Кавасаки, диагностика, лечение, осложнения.04
(Вопросы современной педиатрии. 2010;9(1):104-115)

Об авторах

Г. Гедике
Клиника общей педиатрии, Берлин Медицинский университет, Берлин
Россия


П.Д. Хотама
Клиника общей педиатрии, Берлин Медицинский университет, Берлин
Россия


Б. Хайнкинг
Клиника общей педиатрии, Берлин Медицинский университет, Берлин
Россия


Список литературы

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn. J. Allergy. 1967; 16: 178–222.

2. Kato H., Sugimura T., Akagi T. et al. Long term consequences of Kawasaki disease. A 10 to 21 year follow up study of 594 patients. Circulation. 1996; 94: 1379–1385.

3. Dajani A.S., Taubert K.A., Gerber M.A. et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993; 87: 1776–1780.

4. Taubert K.A., Rowley A.H. Shulman S.T. Nationwide survey of Kawasaki disease and acute rheumatic fever. J. Pediatr. 1991; 119: 279–282.

5. Yanagawa H., Nakamura Y., Yashiro M. et al. Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics. 2001; 107: 33.

6. Holman R.C., Curns A.T., Belay E.D. et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003; 112: 495–501.

7. Gardner–Medwin J.M., Dolezalova P., Cummins C. et al. Incidence of Henoch–Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002; 360: 1197.

8. Chang L.Y., Chang I.S., Lu C.Y. et al. Epidemiologic features of Kawasaki disease in Taiwan, 1996–2002. Pediatrics. 2004; 114: 678.

9. Yanagawa H., Yashiro M., Nakamura Y. et al. Epidemiologic pictures of Kawasaki disease in Japan: From the nationwide incidence survey in 1991 and 1992. Pediatrics. 1995; 95: 475.

10. Rosenfeld E.A., Corydon K.E., Shulman S.T. Kawasaki disease in infants less than 1 year of age. J. Pediatr. 1995; 126: 524.

11. Stockheim J.A., Innocentini N., Shulman S.T. Kawasaki disease in older children and adolescents. J. Pediatr. 2000; 137: 250–252.

12. Chang R.K. Hospitalizations for Kawasaki disease among children in the United States, 1988–1997. Pediatrics. 2002; 109 (6): 87.

13. Momenah T., Sanatani S., Potts J. et al. Kawasaki disease in the older child. Pediatrics. 1998; 102 (1): 7.

14. Hirata S., Nakamura Y., Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr. 2001; 90: 40.

15. Uehara R., Yashiro M., Nakamura Y. et al. Kawasaki disease in parents and children. Acta Paediatr. 2003; 92: 694.

16. Esper F., Shapiro E.D., Weibel C. et al. Association between a novel human coronavirus and Kawasaki disease. J. Infect Dis. 2005; 191: 499–502.

17. Rowley A.H., Eckerley C.A., Jack H.M. et al. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J. Immunol. 1997; 159: 5946–5955.

18. Rowley A.H., Shulman S.T., Spike B.T. et al. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J. Immunol. 2001; 166: 1334–1343.

19. Rowley A.H., Shulman S.T., Mask C.A. et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J. Infect. Dis. 2000; 182: 1183–1191.

20. Takeshita S., Tokutomi T., Kawase H. et al. Elevated serum levels of matrix metalloproteinase–9 (MMP–9) in Kawasaki disease. Clin. Exp. Immunol. 2001; 125: 340–344.

21. Maeno N., Takei S., Masuda K. et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr. Res. 1998; 44: 596–599.

22. Asano T., Ogawa S. Expression of monocyte chemo attractant protein–1 in Kawasaki disease: the anti–inflammatory effect of gamma globulin therapy. Scand J. Immunol. 2000; 51: 98–103.

23. Lin C.Y., Lin C.C., Hwang B. et al. Serial changes of serum interleukin–6, interleukin–8, and tumour necrosis factor alpha among patients with Kawasaki disease. J. Pediatr. 1992; 121: 924–926.

24. Suzuki A., Kamiya T., Kuwuhara N. et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr. cardiol. 1986; 7: 3.

25. Dajani A.S., Taubert K.A., Takahashi M. et al. Guidelines for long tern management of patients with Kawasaki Disease. Report from Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1994; 89: 916–922.

26. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Japan: Ministry of Health and Welfare. Tokyo. 1984.

27. Song D., Yeo Y., Ha K. et al. Risk factors for Kawasaki disease associated coronary abnormalities differ depending on age. Eur. J. Pediatr. 2009; 168 (11): 1315–1321.

28. Anderson TM, Meyer RA, Kaplan S. Long term echocardiographic evaluation of cardiac size and function in patients with Kawasaki disease. Am. Heart J. 1985; 110: 107–115.

29. Hiraishi S., Yashiro K., Oguchi K. et al. Clinical course of cardiovascular involvement in the mucocutaneous lymph node syndrome. Relation between clinical signs of carditis and development of coronary arterial aneurysm. Am. J. Cardiol. 1981; 47: 323–330.

30. Ravekes W.J., Colan S.D., Gauvreau K. et al. Aortic root dilation in Kawasaki disease. Am. J. Cardiol. 2001; 87: 919–922.

31. Nakano H., Nojima K., Saito A. et al. High incidence of aortic regurgitation following Kawasaki disease. J. Pediatr. 1985; 107: 59–63.

32. Landing B.H., Larson E.J. Are infantile periarteritis nodosa with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same: comparison of 20 patients from North America with patients from Hawaii and Japan. Pediatrics. 1977; 59: 651–662.

33. Naoe S., Shibuya K., Takahashi K. et al. Pathological observations concerning the cardiovascular lesions in Kawasaki disease. Cardiol. Young. 1991; 1: 212–220.

34. Suddleson E.A., Reid B., Woolley M.M. et al. Hydrops of the gallbladder associated with Kawasaki syndrome. J. Pediatr. Surg. 1987; 22: 956–959.

35. Sundel R.P., Cleveland S.S., Beiser A.S. et al. Audiologic profiles of children with Kawasaki disease. Am. J. Otol. 1992; 13: 512–515.

36. Knott P.D., Orloff L.A., Harris J.P. et al. Kawasaki Disease Multicenter Hearing Loss Study Group. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am. J. Otolaryngol. 2001; 22: 343–348.

37. Veiga P.A., Pieroni D., Baier W. et al. Association of Kawasaki disease and interstitial nephritis. Pediatr. Nephrol. 1992; 6: 421.

38. Ferriero D.M., Wolfsdorf J.I. Hemolytic uremic syndrome associated with Kawasaki disease. Pediatrics. 1981; 68: 405.

39. Salcedo J.R., Greenberg L., Kapur S. Renal histology of mucocutaneous lymph node syndrome (Kawasaki Disease). Clin. Nephrol. 1998; 29: 47.

40. Hicks R.V., Melish M.E. Kawasaki syndrome. Pediatr. Clin North Am. 1986; 33: 1151–1175.

41. Newburger J.W., Burns J.C., Beiser A.S. et al. Altered lipid profile after Kawasaki Syndrome. Circulation. 1991; 84: 625–631.

42. Salo E., Resonen E., Viikari J. Serum cholesterol levels during and after Kawasaki disease. J. Pediatr. 1991; 119: 557–561.

43. Cabana V.G., Gidding S.S., Getz G.S. et al. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr. Res. 1997; 42: 651–655.

44. Okada T., Harada K., Okuni M. Serum HDL-cholesterol and lipoprotein fraction in Kawasaki disease (acute mucocutaneous lymph node syndrome). Jpn. Circ. J. 1982; 46: 1039–1044.

45. Burns J.C., Mason W.H., Glode M.P. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J. Pediatr. 1991; 118: 680–686.

46. Newburger J.W., Takahashi M., Beiser A.S. et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 1991; 324: 1633–1639.

47. Newburger J.W., Takahashi M., Gerber M.A. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A Statement for Health Professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114: 1708–1733.

48. Durongpisitkul K., Gururaj V.J., Park J.M. et al. The prevention of coronary artery aneurysm in Kawasaki Disease: a meta–analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995; 96: 1057–1061.

49. Lau A.C., Trang T.D., Ito S. et al. Intravenous immunglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheumatism. 2009; 60: 2131–2141.

50. Ogata S., Bando Y., Kimura S. et al. The strategy of immune globulin resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. J. Cardiol. 2009; 53: 15–19.

51. Weiss J.E., Eberhard B.A., Chowdury D. et al. Infliximab as a novel therapy for refractory Kawasaki disease. J. Rheumatol. 2004; 31: 808–810.

52. Oishi T., Fujieda M., Shiraishi T. et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ. Journal. 2008; 72: 850–852.

53. Burns J.C., Mason W.H., Hauger S.B. et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatric. 2005; 146: 662–667.

54. Burns J.C., Best B.M., Mejias A. et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatric. 2008; 153: 833–838.

55. Brogan R.J., Eleftheriou D., Gnanapragasam J. et al. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatr. Rheumatol. 2009; 7: 3.

56. Burtt D.M., Pollack P., Bianco J.A. Intravenous streptokinase in an infant with Kawasaki’s disease complicated by acute myocardial infarction. Pediatr. Cardiol. 1986; 6: 307–311.

57. Cheatham J.P., Kugler J.D., Gumbiner C.H. et al. Intracoronary streptokinase in Kawasaki disease: acute and thrombolysis. Prog. Clin. Biol. Res. 1987; 250: 517–518.

58. Katayama F., Hiraishi S., Takeda N. et al. Intracoronary urokinase and post thrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction. Heart. 1997; 78: 621–622.

59. Kato H., Ichinose E., Inoue O. et al. Intracoronary thrombolytic therapy in Kawasaki disease: treatment and prevention of acute myocardial infarction. Prog. Clin. Biol. Res. 1987; 250: 445–454.

60. Terai M., Ogata M., Sugimoto K. et al. Coronary arterial thrombi in Kawasaki disease. J. Pediatr. 1985; 106: 76–78.

61. Horigome H., Sekijima T., Miyamoto T. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki Disease. Heart. 1997; 78: 517–518.

62. Levy M., Benson L.N., Burrows P.E. et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J. Pediatr. 1991; 118: 467–472.

63. Tsuda E., Kitamura S. Cooperative Study Group of Japan. National survey of coronary artery by pass grafting for coronary stenosis caused by Kawasaki Disease in Japan. Circulation. 2004; 110: 1161–1166.

64. Guidelines for treatment and management of cardiovascular sequelae in Kawasaki Disease. Subcommittee of Cardiovascular Sequelae, Subcommittee of Surgical Treatment, Kawasaki Disease Research Committee. Heart Vessels. 1987; 3: 50–54.

65. Ishii M., Ueno T., Akagi T. et al. Guidelines for catheter intervention in coronary artery lesion in Kawasaki Disease. Pediatr. Int. 2001; 43: 558–562.

66. Checchia P.A., Pahl E., Shaddy R.E. et al. Cardiac transplantation for Kawasaki disease. Pediatrics. 1997; 100: 695–699.

67. Gordon J.B., Kahn A.M., Burns J.C. When children with Kawasaki disease grow up myocardial and vascular complications in adulthood. J. Am. Coll. Cardiol. 2009; 54: 1911–1920.

68. Japanese Circulation Society. Guidelines for the diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ. Journal. 2003; 67 (Suppl. IV):1111–1174.


Для цитирования:


Гедике Г., Хотама П., Хайнкинг Б. БОЛЕЗНЬ КАВАСАКИ — НОВЫЕ ДАННЫЕ. Вопросы современной педиатрии. 2010;9(1):104-115.

For citation:


Gaedicke G., Hotama P., Heineking B. KAWASAKI DISEASE — AN UPDATE. Current Pediatrics. 2010;9(1):104-115. (In Russ.)

Просмотров: 274


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)